Background Third-generation aromatase inhibitors are more eff ective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more eff ective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the effi cacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS.
Introduction
Breast cancer is the most common cancer in women worldwide, with an estimated 1·6 million new cases reported every year. 1 The proportion of these that are diagnosed as ductal carcinoma in situ (DCIS) has substantially increased over the past few decades due to the introduction of mammographic screening. It is estimated that approximately a fi fth of all screen-detected breast cancers are DCIS. 2 Management strategies for DCIS vary depending on histological grade, tumour characteristics, and extent of disease. Almost all aspects of treatment are controversial, including the need for any treatment for some screendetected lesions, 3 the extent of surgery, 4 the use of radiotherapy, 5, 6 and the use of adjuvant endocrine therapy. 7, 8 The role of tamoxifen has been investigated in two large trials. 7, 8 In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 trial, 7 all women with DCIS received radiotherapy before being randomly assigned to tamoxifen or matching placebo. After a median of 6 years of follow-up, a signifi cant 37% reduction in breast cancer recurrence was observed with tamoxifen compared with placebo. 7 Retrospective evaluation of oestrogen receptors (ER) and progesterone receptors (PgR) in 732 patients from the original study showed that tamoxifen reduced subsequent breast cancer events by 51% for women with ER-positive DCIS. 9 However, no signifi cant benefi t with tamoxifen was observed for women with ER-negative DCIS. In the UK/ANZ DCIS trial, 8 1578 women with locally excised DCIS were randomly assigned to receive tamoxifen with or without radiotherapy. After a median of 12·7 years of follow-up, tamoxifen signifi cantly reduced all new breast cancer events by 29%, with a signifi cant impact on ipsilateral DCIS recurrence and contralateral tumours, but no eff ect on ipsilateral invasive recurrence. 8 Until now no data have been available on the use of aromatase inhibitors for DCIS. Two trials of very similar design have been conducted. Both compared anastrozole with tamoxifen in postmenopausal women with ERpositive or PgR-positive DCIS. The NSABP B-35 results will be reported elsewhere. 10 Here, we report the fi rst results from the International Breast Cancer Intervention Study-II DCIS (IBIS-II DCIS).
Methods

Study design and participants
We undertook a double-blind, randomised, placebocontrolled trial to compare anastrozole with tamoxifen for the prevention of locoregional and contralateral breast cancer. Participants were women aged 40-70 years, postmenopausal, and had DCIS diagnosed within 6 months before randomisation. Microinvasion of less than 1 mm was permitted. Patients treated by mastectomy were not eligible for this study but could be included in the IBIS-II breast cancer prevention trial.
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Radiotherapy was permitted according to local practice. Margin status was determined by the local pathologist and ER and PgR positivity was determined as greater than or equal to 5% positive cells (equivalent of Quickscore of three or above and H-score of ten or above). After a protocol amendment on Feb 24, 2009, women were also allowed to enter the trial if they had been diagnosed with atypical hyperplasia or lobular carcinoma in situ to allow treatment of these benign breast diseases known to respond to tamoxifen. 12, 13 Exclusion criteria were: premenopausal at diagnosis; any previous diagnosis of breast cancer (including DCIS excised more than 6 months before randomisation or treated by mastectomy); diagnosis of any other cancer in the past 5 years (excluding non-melanoma skin cancer or in-situ cervical cancer); current treatment with anticoagulants; previous diagnosis of deep-vein thrombosis, transient ischaemic attack, or cerebrovascular accident; previous or current use of selective oestrogen receptor modulators; intention to use menopausal hormone therapy; unexplained postmenopausal bleeding; evidence
Research in context
Evidence before this study A PubMed search between Jan 1, 1990, and Dec 31, 2002 (with the terms "ductal carcinoma in situ", "breast cancer", "aromatase inhibitors", and "endocrine therapy") and discussion with colleagues yielded no clinical trials or large cohorts of women with ductal carcinoma in situ (DCIS) treated by aromatase inhibitors. There have been two previous trials of tamoxifen. In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 trial, all women with DCIS received radiotherapy before being randomly assigned to tamoxifen or matching placebo. After a median of 6 years of follow-up, a signifi cant 37% reduction in breast cancer recurrence was observed with tamoxifen compared with placebo. In the UK/ANZ DCIS trial, 1578 women with locally excised DCIS were randomly assigned to receive tamoxifen with or without radiotherapy. After a median of 12·7 years of follow-up, tamoxifen signifi cantly reduced all new breast cancer events by 29%, with a signifi cant eff ect on ipsilateral DCIS recurrence and contralateral tumours, but no eff ect on ipsilateral invasive recurrence. A further PubMed search was performed in October, 2015, which found no further published articles except the NSABP B-35 trial conference abstract.
Added value of this study
In combination with the B-35 trial, this trial provides the fi rst evidence for the use of an aromatase inhibitor (here, anastrozole) compared with tamoxifen for postmenopausal women with locally excised hormone-receptor-positive DCIS after a median follow-up of 7·1 years. In this study, no clear effi cacy diff erences were seen between the two treatments, although all available evidence supports a greater effi cacy for anastrozole.
Implications of all the available evidence
Our results are consistent with the small benefi t of anastrozole versus tamzifen as seen in the NSABP B-35 trial. This is also supported by direct evidence of greater effi cacy for recurrence in adjuvant trials of women with early invasive cancer and indirect evidence of greater effi cacy against new cancers in a preventive setting. Side-eff ect profi les between the drugs diff ered, but there was no clear overall advantage for either treatment. Anastrozole off ers another treatment option for postmenopausal women with oestrogen-receptor-positive DCIS which might be more appropriate for some women with contraindications to tamoxifen.
of severe osteo porosis (T-score less than -4 at total hip or lumbar spine or more than two fragility fractures); history of lactose intolerance, glucose intolerance, or both; or life expectancy judged by the clinician to be less than 10 years.
All women provided written informed consent and the study was approved by the ethics committees of all participating institutions. The study sponsor was Queen Mary University of London.
Randomisation and masking
Participants were randomly assigned in a 1:1 ratio to receive 1 mg/day oral anastrozole or 20 mg/day oral tamoxifen. Randomisation was stratifi ed by major centre or hub. Randomised blocks (six, eight, or ten) were used to maintain balance and randomisation was performed centrally by electronic contact with the main trials centre. All treatment was given on a daily basis for 5 years and all women took two tablets per day (tamoxifen and anastrozole placebo, or anastrozole and tamoxifen placebo). All IBIS-II DCIS personnel, participants, and clinicians were masked to treatment allocation, except for the IBIS-II DCIS trial statistician, who had access to unblinded data, and the independent data monitoring committee, who reviewed interim data for safety purposes.
Procedures
A dual-energy x-ray absorptiometry scan within 2 years before entry to the trial and two lateral spinal radiographs were required to assess bone density and vertebral fractures. Women were seen at 6 months, 12 months, and then annually up to the 5 year follow-up point at local clinics. Adherence to treatment was ascertained at each follow-up visit. After 5 years, followup was annual and either by a short postal questionnaire or clinic visit, depending on country. Clinical adverse events were recorded during the post-treatment followup period. Mammograms were performed at least every 2 years. Blood samples were taken at baseline, year 1, and year 5 for the evaluation of potential biomarkers.
Outcomes
The primary endpoint of this analysis was the development of histologically confi rmed breast cancer, both invasive and new or recurrent DCIS. First events were further categorised as local recurrence (all ipsilateral disease), distant recurrence (including node-positive contralateral disease and recurrences at distant sites [eg, lung, bone, etc]), or isolated contralateral events. Secondary endpoints included ER status, breast cancer mortality, other cancers, cardiovascular disease, fractures, adverse events, and non-breast cancer deaths. Prespecifi ed subgroup analyses of recurrence were for invasive versus DCIS, contralateral versus ipsilateral, and ER status (ER positive vs ER negative); other subgroup analyses were exploratory. Further post-hoc analyses included PgR and HER2 receptor status for invasive recurrence only. Future plans are to explore outcomes by ER levels and HER2 status of the primary tumour when tissue collection is complete, and to examine timing eff ects of treatment after the initial 5 year treatment period is completed.
Statistical analysis
All analyses were done on a modifi ed intention-to-treat basis, including all women who were enrolled, randomly assigned, and did not revoke consent for use of their data. Analyses of the effi cacy endpoints were based on hazard ratios (HRs). Cox proportional hazard models 14, 15 were used to derive these with corresponding 95% CIs.
The analysis plan fi rst tested non-inferiority of anastrozole (upper 95% CI of HR <1·25) and, if successful, then for the superiority of anastrozole. Survival curves were estimated using the Kaplan-Meier method. 16 Secondary endpoints were compared using odds ratios (ORs), which closely approximate relative risk for rare events. Adverse events are presented if predefi ned or occurred in at least 5% of participants, and Fisher's exact tests were used to compare adverse events when appropriate. Adherence was calculated using the Kaplan-Meier method, censoring at breast cancer recurrence, death, or 5 years of follow-up. All p values were two-sided.
We estimated a required sample size of 4000 on the basis of a 1·6% annual recurrence rate for tamoxifentreated patients with a 16·7% relative reduction for anastrozole to show non-inferiority, and a 33% reduction to show superiority with 5-year median follow-up. Recruitment to the trial closed on Feb 8, 2012, after enrolment of 2980 of the 4000 planned participants. During the course of the trial, local recurrences occurred at less than half the rate anticipated in the analysis plan, due largely to improvements in the surgical treatment of DCIS. Consequently, the required numbers of events anticipated in the protocol would not be reached for a number of years, and the IBIS-II steering committee, with the agreement of the independent data monitoring committee, took the decision to analyse and report the results at this stage; data were collected up to the cutoff date of Sept 30, 2015.
All analyses were done using Stata version 13.1. This trial is registered at the ISRCTN registry, number ISRCTN37546358.
Role of the funding source
The study funders had no role in design, data collection, data analysis, data interpretation, or writing of the report. IS had full access to all data in the study, and JC, JFF, and AH had fi nal responsibility for the decision to submit for publication. table 1 . A further 26 women were found to be ineligible after randomisation (fi gure 1) but were included in the primary analysis. Median age was 60·3 years (IQR 56·1-64·6), and 658 (22%) were older than 65 years. Median body-mass index was 26·7 kg/m² (IQR 23·6-30·4), with 903 (31%) of women being obese (>30 kg/m²) at baseline (table 1). Median age at menarche was 13 years (IQR [12] [13] [14] and at birth of fi rst child was 24 years (IQR 21-27), and 814 (28%) women had had a hysterectomy before trial entry. 1336 (45%) women had used menopausal hormone therapy before trial entry and two-thirds were never-smokers (table 1) . Only nine women (<1%) with atypical hyperplasia or lobular carcinoma in situ were entered into the trial.
Results
Between
Baseline DCIS tumour characteristics are also shown in The cutoff date for this analysis was Sept 30, 2015. Median follow-up was 7·2 years (IQR 5·6-8·9) and 21 112 women-years of follow-up were accrued (10 670 women-years for anastrozole and 10 442 tamoxifen). 5 year adherence was estimated to be 67·6% (95% CI 65·1-70·0) in the anastrozole group compared with 67·4% (64·9-69·7) in the tamoxifen group (p=0·71; appendix). The main reasons for treatment cessation were adverse events and patient decision (data not shown).
A total of 144 breast cancer recurrences were reported; recurrences were mostly invasive (84 [58%]; table 2). Numerically fewer recurrences occurred with anastrozole (67 recurrences; annual rate 0·64% [95% CI 0·50-0·82]) than for tamoxifen (77; 0·72% [0·58-0·90]; HR 0·89 [95% CI 0·64-1·23]; fi gure 2). The noninferiority of anastrozole was established (upper 95% CI <1·25), but its superiority to tamoxifen was not (p=0·49). Kaplan-Meier estimates of recurrence at 5 years were 2·5% (95% CI 1·8-3·5) for anastrozole and 3·0% (2·2-4·0) for tamoxifen. After 10 years of follow-up, recurrence was 6·6% (95% CI 4·9-8·8) and 7·3% (5·7-9·4), respectively.
Among the 144 recurrences, 86 (60%) were ER-positive, 30 (21%) were ER-negative, and ER status was missing for 28 (19%). Among women with ER-positive recurrences, 30 (2%) were in the anastrozole group compared with 56 (4%) in the tamoxifen group (HR 0·55 [95% CI 0·35-0·86], p=0·008). Among women with ERnegative recurrences, 17 (1%) were in the anastrozole group compared with 13 (<1%) in the tamoxifen group (HR 1·34 [95% CI 0·65-2·75], p=0·43).
Analyses adjusted by age, body-mass index, menopausal hormone therapy use, grade, margins, and radiotherapy subgroups yielded similar HRs as in the univariate analyses (table 2) . Similar numbers of DCIS recurrences were observed in each treatment group (29 for anastrozole vs 30 for tamoxifen; HR 0·99 [95% CI 0·60-1·65], p=0·98; table 2).
A total of 69 deaths had been reported by the cutoff date (appendix). Overall, we noted no statistically signifi cant diff erence between treatment arms (33 for anastrozole vs 36 for tamoxifen; HR 0·93 [95% CI 0·58-1·50], p=0·78) and no specifi c cause of death diff ered by treatment group. Only four deaths from breast cancer were recorded, one in the anastrozole group and three in the tamoxifen group. Overall, the frequency of cancers other than breast was not signifi cantly diff erent in the anastrozole and tamoxifen groups (61 vs 71; OR 0·88 [95% CI 0·61-1·26], p=0·47; table 3). However, endometrial, ovarian, and skin cancers were signifi cantly more common with tamoxifen (table 2) .
We collected a comprehensive record of side-eff ects during the 5 years of treatment ( Despite the diff erences in side-eff ect profi les, treatment adherence was virtually identical between treatment groups and was 67·6% for anastrozole and 67·4% for tamoxifen after 5 years (appendix).
In a post-hoc analysis, we assessed diff erences by subgroups of tumour for invasive recurrence (fi gure 3). The largest diff erence was noted for invasive ER-positive/ HER2-negative tumours (10 recurrences with anastrozole vs 28 with tamoxifen; HR 0·37 [95% CI 0·18-0·75], p=0·0060; fi gure 3). HER2-positive tumours showed better effi cacy with tamoxifen (HR 1·62 [95% CI 0·53-4·96]; heterogeneity p=0·05; fi gure 3).
We did not fi nd a diff erential eff ect on recurrence according to radiotherapy use at baseline (54 recurrences with radiotherapy vs 30 with no radiotherapy; HR 0·77 [95% CI 0·49-1·21], p=0·25). Furthermore, anastrozole was not more eff ective at reducing invasive recurrences in those women who had radiotherapy at baseline (HR 0·77 [95% CI 0·45-1·32], p=0·34) compared with those who did not (0·86 [0·42-1·77], p=0·69; heterogeneity p=0·79; fi gure 3).
In a post-hoc analysis, we excluded 26 women who were found to be ineligible after randomisation (fi gure 1). Exclusion of these women from the primary analysis did not alter the results (data not shown). Furthermore, exclusions of the nine (<1%) women with atypical hyperplasia or lobular carcinoma in-situ from a post-hoc reassessment of the primary endpoint analysis had no eff ect on the results (data not shown).
Discussion
In this large, randomised, double-blind, placebocontrolled trial comparing anastrozole with tamoxifen in women with ER-positive or PgR-positive DCIS treated by wide local excision with or without breast radiotherapy, the non-inferiority of anastrozole to tamoxifen was demonstrated, but a signifi cant superiority effi cacy was not, although we noted a slightly lower recurrence rate for anastrozole. However, the overall event rate was lower than anticipated, which might have contributed to nonsignifi cant results with wide confi dence intervals, and as a result smaller eff ects of anastrozole might have been missed. This possible small benefi t for anastrozole is consistent with the larger 27% reduction seen in the similar NSABP B-35 trial, which was statistically signifi cant (p=0·03). 10 Trials in the adjuvant setting have also indicated greater effi cacy for anastrozole and other aromatase inhibitors versus tamoxifen. 17, 18 Additionally, the reduction in contralateral breast cancer is consistent with the benefi ts of anastrozole compared with tamoxifen seen in the ATAC trial 17 and compared with placebo in the IBIS-II breast cancer prevention trial. 11 The greater effi cacy of anastrozole for ER-positive or HER2-negative invasive recurrence has been seen elsewhere for invasive disease.
19 HER2 status was not routinely collected for the baseline tumour, but tumour blocks are being collected retrospectively and its impact along with other markers will be reported at a later stage. Local recurrence rates were lower than those predicted on the basis of earlier trials. This is probably caused by greater attention to Clear diff erences were seen in the side-eff ect profi le. Many side-eff ects followed the expected pattern seen during treatment of invasive cancer, 18 with a higher fracture rate and more musculoskeletal events with anastrozole, and more venous thromboembolic events, gynaecological events, and vasomotor symptoms with tamoxifen. The higher rate of strokes with anastrozole is surprising because this pattern was not seen in ATAC (62 strokes with anastrozole vs 80 with tamoxifen), 17 or the prevention component of IBIS-II (three with anastrozole vs six with placebo), 11 and these events were not lower for tamoxifen when compared with placebo in IBIS-I (ten with tamoxifen vs 12 with placebo). 20 Tamoxifen has previously been reported to reduce headache occurrence, 20, 21 so the higher rate of headache in the anastrozole group of our trial probably resulted from this rather than the eff ects of anastrozole. However, increased hypertension was seen for anastrozole in both ATAC 17 and IBIS-II prevention; 11 the small increase in our anastrozole group therefore seems to be a real treatment eff ect, although the mechanism is not understood.
Although occurrence of other cancers was similar overall, the incidence of specifi c cancers diff ered by treatment. A two-to-three-fold increase in endometrial cancer is well documented for tamoxifen, 22, 23 by contrast with a reduced incidence compared with the general population anticipated for anastrozole in view of the strong hormone dependence for this tumour. 24 In combination, these two eff ects account for the striking diff erence seen here. Ovarian cancer is not known to be aff ected by tamoxifen and the diff erences here probably result from a preventive eff ect of anastrozole, as previously seen in IBIS-II prevention (four cases with anastrozole vs seven with placebo) and indirectly in ATAC (ten with anastrozole vs 17 with tamoxifen), and supported by the increased risk associated with use of menopausal hormone therapy. 25 A decrease of colorectal cancer has been reported in users of menopausal hormone therapy; 26 although a small increase was reported in ATAC (39 cases with anastrozole vs 31 with tamoxifen), a lower risk was seen in IBIS-II prevention (three with anastrozole vs 11 with tamoxifen), so the role of aromatase inhibitors in aff ecting risk of colorectal cancer remains uncertain.
The major strengths of this study include its multinational nature, large size, moderate length of follow-up, and detailed collection of side-eff ect data. The major limitation of this trial was the lower-than-expected event rate, which adds uncertainty about the lack of signifi cance of some of the small diff erences seen. A few unexpected side-eff ects were also recorded, which require further validation in view of the amount of multiple testing. It is too early to assess the eff ect of these treatments on mortality and long-term follow-up; a full meta-analysis of all major endpoints with the B-35 study is planned to study these issues.
In summary, anastrozole off ers another option for postmenopausal women with ER-positive DCIS, and the choice between it and tamoxifen will probably depend more on previous history of other conditions (eg, osteoporosis and venous thrombosis) and short-term tolerability (musculoskeletal, vasomotor, and gynaecological symptoms) than diff erences in effi cacy.
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